Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer AG

www.bayer.com

Latest From Bayer AG

Exelixis CEO Eyes Expanded Indications For Cabozantinib

In a video interview at the Biotech Showcase, Exelixis CEO Michael Morrissey discusses the recent launch of cabozantinib in first-line renal cell carcinoma and looks ahead to filing soon in liver cancer.

ImmunoOncology Clinical Trials

CSL Looks Beyond Organic Growth To External Innovation

CSL Ltd.'s sales grew 15% in its last fiscal year and are expected to grow about 8% in FY 2018, but the Australia-based company is looking beyond its plasma protein expertise to outside innovation to help boost future revenue.

Business Strategies Companies

Vitamin C Pricing In Supreme Court, Vitamin D QHC Petition Fails: Health And Wellness Industry News

Supreme Court will hear an appeal of a circuit court's reversal of a ruling that two vitamin C importers violated US antitrust laws by conspiring to fix prices; Bayer request for vitamin D QHC for multiple sclerosis rejected; Inno-Vita warned on cleansing drug claims; and 'Prevention' clear in ABC-AHP-NCNPR program name.

United States Dietary Supplements

J.P. Morgan Notebook Day 2: Walmsley On Diversity, Amgen's Overseas Cash, Growing Opdivo, Mylan On US Generic Pricing, Boston's Pipeline And J&J In Alzheimer's

Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference in San Francisco: GSK's Walmsley looks to be a leader on diversity, Amgen talks tax reform and deals, Mylan raises the issue of generic drug shortages, Boston builds out its pipeline, and J&J is dealing in Alzheimer's disease.

Deals Clinical Trials
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register